IAVI Report

IAVI Report is a scientific publication that provides comprehensive and editorially independent coverage of HIV vaccine and prevention research, as well as the quest to develop vaccines and other preventive technologies to address other global health priorities. The publication features the voices and opinions of those leading these efforts and provides an unparalleled analysis of the latest scientific and policy research.

To access archived issues of IAVI Report dating back to 1996, click here.

Subscribe now to receive IAVI Report right to your inbox.

Questions/comments? Email us at This email address is being protected from spambots. You need JavaScript enabled to view it..

  • Editor's Letter
  • A step in the right direction

    Researchers describe the experimental HIV vaccine approach called germline targeting as “shepherding” the immune system. They hope it will lead to greener pastures.

  • Leading Africa’s COVID-19 response

    John Nkengasong warns against complacency setting in as vaccines trickle into many African countries.

  • A tale of two pandemics

    In conversation with four experts who are applying lessons from the decades-long battle against HIV/AIDS to the ongoing COVID-19 pandemic.

    • The future of antibody-based HIV prevention

      The highly anticipated results from recent HIV prevention trials, and how the field acts on them, may have important implications for future research. This special report identifies the main issues researchers are contemplating in the aftermath of the first trials to test whether a broadly neutralizing antibody could protect people from HIV infection. Read more to find out what 21 leading experts in the field have to say about the future of antibody-based HIV prevention.

            • Editor's Letter
            • Is there an HIV prevention crisis?

              More HIV-infected people than ever before are receiving life-saving treatment. Despite this progress, HIV incidence rates remain virtually static.

            • Coding for protection

              Although challenges remain, the growing field of mRNA-based vaccine development seems to have a bright future, with potential for preventing cancer, flu, and HIV.

            • An industry leader in HIV research

              Paul Stoffels of Johnson & Johnson talks about the company’s broad HIV portfolio and the role of industry in advancing vaccine research.

            • Overflowing with antibodies and optimism

              There is more optimism than ever that researchers are on the path to developing vaccines and antibodies that can help stem HIV’s persistent spread.